Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials
Chronic kidney disease (CKD) is common in patients with type 2 diabetes mellitus (T2DM) and limits therapeutic options. Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a novel class of oral glucose-lowering agents and are known to be safe and effective in the general population. We searched Coch...
Saved in:
Published in | Nephron (2015) Vol. 136; no. 2; p. 85 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
01.01.2017
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Chronic kidney disease (CKD) is common in patients with type 2 diabetes mellitus (T2DM) and limits therapeutic options. Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a novel class of oral glucose-lowering agents and are known to be safe and effective in the general population.
We searched Cochrane, EMBASE, and PubMed from the time of their inception until March 2015. We included randomized controlled trials analyzing the efficacy (change in hemoglobin A1C [HbA1C]) and safety of DPP-4 agents in individuals with reduced kidney function (estimated glomerular filtration rate <60 mL/min/1.73 m2). We extracted study characteristics, participants' baseline characteristics, and safety outcomes from eligible studies. We performed a random effects meta-analysis to summarize the change in HbA1C and the relative risk of cardiovascular events in patients with T2DM and CKD. We also collected data on hypoglycemia, other serious adverse events, and mortality.
We reviewed 12 studies with 4,403 patients with CKD and 239 on dialysis, finding a mean weighted decline in HbA1C of -0.48 (95% CI -0.61 to -0.35) with DPP-4 inhibitor therapy compared to placebo. DPP-4 inhibitors did not result in any additional adverse events, hypoglycemic episodes, or increased mortality. Restricting to studies with low risk of bias did not alter these findings.
DPP-4 inhibitors can lower HbA1C without increasing the risk of cardiovascular or other major adverse events in patients with CKD. Few studies reported critical adverse events such as heart failure and hypersensitivity. If compared with other oral antiglycemic drugs, the effect of DPP-4 inhibitors is limited; however, their low risk of hypoglycemia may favor their use in patients with CKD.
This systematic review of DPP-4 inhibitors in CKD suggests that they reduce HbA1C by about 0.5%. Furthermore, there was not any increase in the risk for significant adverse events. More research is needed to determine the safety and efficacy of DPP-4 inhibitors in CKD. |
---|---|
AbstractList | Chronic kidney disease (CKD) is common in patients with type 2 diabetes mellitus (T2DM) and limits therapeutic options. Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a novel class of oral glucose-lowering agents and are known to be safe and effective in the general population.
We searched Cochrane, EMBASE, and PubMed from the time of their inception until March 2015. We included randomized controlled trials analyzing the efficacy (change in hemoglobin A1C [HbA1C]) and safety of DPP-4 agents in individuals with reduced kidney function (estimated glomerular filtration rate <60 mL/min/1.73 m2). We extracted study characteristics, participants' baseline characteristics, and safety outcomes from eligible studies. We performed a random effects meta-analysis to summarize the change in HbA1C and the relative risk of cardiovascular events in patients with T2DM and CKD. We also collected data on hypoglycemia, other serious adverse events, and mortality.
We reviewed 12 studies with 4,403 patients with CKD and 239 on dialysis, finding a mean weighted decline in HbA1C of -0.48 (95% CI -0.61 to -0.35) with DPP-4 inhibitor therapy compared to placebo. DPP-4 inhibitors did not result in any additional adverse events, hypoglycemic episodes, or increased mortality. Restricting to studies with low risk of bias did not alter these findings.
DPP-4 inhibitors can lower HbA1C without increasing the risk of cardiovascular or other major adverse events in patients with CKD. Few studies reported critical adverse events such as heart failure and hypersensitivity. If compared with other oral antiglycemic drugs, the effect of DPP-4 inhibitors is limited; however, their low risk of hypoglycemia may favor their use in patients with CKD.
This systematic review of DPP-4 inhibitors in CKD suggests that they reduce HbA1C by about 0.5%. Furthermore, there was not any increase in the risk for significant adverse events. More research is needed to determine the safety and efficacy of DPP-4 inhibitors in CKD. |
Author | Komenda, Paul Walker, Simon R MacDonald, Kerry Tangri, Neil Al-Tuwaijri, Wafa Tangri, Navdeep Hiebert, Brett Ferguson, Thomas W Khojah, Suhail Nadurak, Stewart W D Rigatto, Claudio |
Author_xml | – sequence: 1 givenname: Simon R surname: Walker fullname: Walker, Simon R organization: Chronic Disease Innovation Center, Winnipeg, MB, Canada – sequence: 2 givenname: Paul surname: Komenda fullname: Komenda, Paul – sequence: 3 givenname: Suhail surname: Khojah fullname: Khojah, Suhail – sequence: 4 givenname: Wafa surname: Al-Tuwaijri fullname: Al-Tuwaijri, Wafa – sequence: 5 givenname: Kerry surname: MacDonald fullname: MacDonald, Kerry – sequence: 6 givenname: Brett surname: Hiebert fullname: Hiebert, Brett – sequence: 7 givenname: Neil surname: Tangri fullname: Tangri, Neil – sequence: 8 givenname: Stewart W D surname: Nadurak fullname: Nadurak, Stewart W D – sequence: 9 givenname: Thomas W surname: Ferguson fullname: Ferguson, Thomas W – sequence: 10 givenname: Claudio surname: Rigatto fullname: Rigatto, Claudio – sequence: 11 givenname: Navdeep surname: Tangri fullname: Tangri, Navdeep |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28178698$$D View this record in MEDLINE/PubMed |
BookMark | eNo1T1tLwzAYDaK4i3vwD0j-QLW5NvFtdF6GA2XO55EmX1mkTUtTlfrrLeqezuHc4MzQaWgCIHRJ0mtChL5J05QLLhU7QVNKmUgYUXKCFjG-jxZlhGnGz9GEKpIpqdUUhZVvoe29Gyr88ktMhITjdTj4wvdNF7EPOD90TfAWP3kXYMArH2GM3eIlfh1iD7XpR3MLnx6-cFPirQmuqf03OJxXfiyaCu86b6p4gc7KEWDxj3P0dn-3yx-TzfPDOl9uEssy2ifGZkQIK5SQBWMmy1JNtQRHGXBhy1EinIAuypTJUhktLHHalBSUtAY4oXN09bfbfhQ1uH3b-dp0w_54nP4AvzJaQw |
CitedBy_id | crossref_primary_10_1159_000515704 crossref_primary_10_1097_TP_0000000000003867 crossref_primary_10_1002_14651858_CD011798_pub2 crossref_primary_10_3389_fphar_2021_781379 crossref_primary_10_1111_dom_13986 crossref_primary_10_3390_jcm9113578 crossref_primary_10_1080_13543784_2019_1592156 crossref_primary_10_1186_s12916_020_01616_8 crossref_primary_10_4140_TCP_n_2022_477 crossref_primary_10_3390_antiox10020246 crossref_primary_10_1161_CIRCULATIONAHA_117_031883 crossref_primary_10_3390_ijms232213749 crossref_primary_10_1038_s41574_020_0399_8 crossref_primary_10_3390_molecules27103055 crossref_primary_10_1111_jdi_13564 crossref_primary_10_1111_1753_0407_13067 crossref_primary_10_26442_22217185_2019_2_190317 crossref_primary_10_1016_j_diabres_2020_108604 crossref_primary_10_1080_14740338_2018_1444027 crossref_primary_10_1016_j_diabet_2018_10_003 crossref_primary_10_1016_j_metabol_2020_154295 crossref_primary_10_1016_j_jacc_2018_03_477 crossref_primary_10_3390_jcm11061521 |
ContentType | Journal Article |
Copyright | 2017 S. Karger AG, Basel. |
Copyright_xml | – notice: 2017 S. Karger AG, Basel. |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1159/000454683 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
EISSN | 2235-3186 |
ExternalDocumentID | 28178698 |
Genre | Meta-Analysis Journal Article Review |
GroupedDBID | 0R~ 30W 327 4.4 53G 7X7 88E 8AO 8FI 8FJ ABUWG ACGFS ADBBV AENEX AFKRA AFOSN ALMA_UNASSIGNED_HOLDINGS AZPMC BENPR BPHCQ BVXVI CCPQU CGR CUY CVF CYUIP EBS ECM EIF EJD EMB EMOBN F5P FYUFA HMCUK HZ~ KUZGX M1P NPM O1H O9- PQQKQ PROAC PSQYO RKO RXVBD S0X SV3 UKHRP |
ID | FETCH-LOGICAL-c372t-ac7155c5856b33a7709296ed23e45cf33a141e9bf036f8a95c1d9af2e86cae412 |
IngestDate | Fri May 24 00:03:44 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Dipeptidyl peptidase-4 inhibitors Chronic kidney disease Type 2 diabetes mellitus |
Language | English |
License | 2017 S. Karger AG, Basel. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c372t-ac7155c5856b33a7709296ed23e45cf33a141e9bf036f8a95c1d9af2e86cae412 |
PMID | 28178698 |
ParticipantIDs | pubmed_primary_28178698 |
PublicationCentury | 2000 |
PublicationDate | 2017-01-01 |
PublicationDateYYYYMMDD | 2017-01-01 |
PublicationDate_xml | – month: 01 year: 2017 text: 2017-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Nephron (2015) |
PublicationTitleAlternate | Nephron |
PublicationYear | 2017 |
SSID | ssj0002313934 |
Score | 2.3072858 |
SecondaryResourceType | review_article |
Snippet | Chronic kidney disease (CKD) is common in patients with type 2 diabetes mellitus (T2DM) and limits therapeutic options. Dipeptidyl peptidase-4 (DPP-4)... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 85 |
SubjectTerms | Aged Aged, 80 and over Clinical Trials as Topic Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Female Glycated Hemoglobin A - analysis Humans Male Middle Aged Randomized Controlled Trials as Topic Renal Insufficiency, Chronic - drug therapy |
Title | Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28178698 |
Volume | 136 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECWc9tJL0aL7Bh56C9haFEVSvRlNi6BGgyJxkNwCrrAMR_bBQZH8Qn66Q5GyCHdB24sskJAg6T2PhqOZNwi9VZKLMTOcUE5rwowpifZeEEGVttToeixDofDXI354yr6cV-ej0W2WtXS10e_MzS_rSv4HVRgDXEOV7D8guz0pDMA-4AtbQBi2f4XxQbMOSSn2ern_rduBVxJh8J-fN7rp2uiEmr4of7s_bWwLBuAgfpGJFekng47z8baG5Vi1dnXZ3ITYb183OevuJvdkj9w6nDh4qPB2r7KIwplaplSNEyBCO6QkToPag1W7CYnT-Wqh5jFFaJ6lfEyWZHb1XTWLWAx_przKYxSFyGIUrrNl4ISED-5J9bo3vFH6JDGMZmY0dvH52bpXdUyHZBXjsf9NhvL6soOZykJIHltb_3l2R2i7n9pDe_AbeqimwM-iUwUCV7lkSZsKLuT99jKCnnQ6dGdt0vkoswfoflpc4ElkykM0cu0j1A4swRlL8MAS3LQ4sQRHluDEkg94ggeO4MgRvPJ44AjuOYIjRx6j08-fZh8PSeqyQUwp6IYoI8CnNLBs5LoslRBj8Ji5s7R0rDIehgpWuFp78HW8VHVlClsrT53kRjlW0CfoTrtq3TOEuayV5cywSsCx3EqtK-ddWdBxaZxUz9HT-Hgu1lFK5aJ_cC9-O_MS3RsY9Qrd9XAn7jU4ghv9poPoB5-UXZI |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dipeptidyl+Peptidase-4+Inhibitors+in+Chronic+Kidney+Disease%3A+A+Systematic+Review+of+Randomized+Clinical+Trials&rft.jtitle=Nephron+%282015%29&rft.au=Walker%2C+Simon+R&rft.au=Komenda%2C+Paul&rft.au=Khojah%2C+Suhail&rft.au=Al-Tuwaijri%2C+Wafa&rft.date=2017-01-01&rft.eissn=2235-3186&rft.volume=136&rft.issue=2&rft.spage=85&rft_id=info:doi/10.1159%2F000454683&rft_id=info%3Apmid%2F28178698&rft_id=info%3Apmid%2F28178698&rft.externalDocID=28178698 |